KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Other Non-Current Assets: 2010-2025

Historic Other Non-Current Assets for TherapeuticsMD (TXMD) over the last 10 years, with Sep 2025 value amounting to $470,000.

  • TherapeuticsMD's Other Non-Current Assets rose 710.34% to $470,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $470,000, marking a year-over-year increase of 710.34%. This contributed to the annual value of $130,000 for FY2024, which is 62.21% down from last year.
  • Latest data reveals that TherapeuticsMD reported Other Non-Current Assets of $470,000 as of Q3 2025, which was up 9.81% from $428,000 recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's Other Non-Current Assets registered a high of $48.7 million during Q4 2021, and its lowest value of $58,000 during Q2 2024.
  • For the 3-year period, TherapeuticsMD's Other Non-Current Assets averaged around $232,182, with its median value being $253,000 (2023).
  • Examining YoY changes over the last 5 years, TherapeuticsMD's Other Non-Current Assets showed a top increase of 19,149.80% in 2021 and a maximum decrease of 99.53% in 2021.
  • TherapeuticsMD's Other Non-Current Assets (Quarterly) stood at $48.7 million in 2021, then plummeted by 99.48% to $253,000 in 2022, then spiked by 35.97% to $344,000 in 2023, then crashed by 62.21% to $130,000 in 2024, then surged by 710.34% to $470,000 in 2025.
  • Its Other Non-Current Assets stands at $470,000 for Q3 2025, versus $428,000 for Q2 2025 and $211,000 for Q1 2025.